MA 17.03 Prognostic Value of the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Completely Resected Stage IIIA(N2) NSCLC

Q. Zhang; X. Fu; X. Cai; W. Feng

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >MA 17.03 Prognostic Value of the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Completely Resected Stage IIIA(N2) NSCLC

【24h】

MA 17.03 Prognostic Value of the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Completely Resected Stage IIIA(N2) NSCLC

机译：MA 17.03新的IASLC / ATS / ERS / ERS肺腺癌分类的预后价值IIIA（N2）NSCLC

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第11期|共2页
作者
Q. Zhang; X. Fu; X. Cai; W. Feng;
展开▼
作者单位

Radiation Oncology Hanghai Chest Hospital Shanghai Jiao Tong University;

Radiation Oncology Shanghai Chest Hospital Shanghai Jiao Tong University;

Radiation Oncology Shanghai Chest Hospital Shanghai Jiao Tong University;

Radiation Oncology Shanghai Chest Hospital Shanghai Jiao Tong University;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. MA 17.03 Prognostic Value of the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Completely Resected Stage IIIA(N2) NSCLC [J] . Q. Zhang, X. Fu, X. Cai, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：MA 17.03新的IASLC / ATS / ERS / ERS肺腺癌分类的预后价值IIIA（N2）NSCLC
2. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients [J] . RussellP.A., BarnettS.A., WalkiewiczM., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2013,第4期

机译：根据新的IASLC / ATS / ERS三期（N2）患者的IASLC / ATS / ERS肺腺癌分类，突变状态和生存与主要组织学亚型的相关性
3. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: A clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification [J] . ZhangJ., WuJ., TanQ., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2013,第9期

机译：为什么病理性IA期肺腺癌与预后会有所不同？：根据IASLC / ATS / ERS分类对176例病理性IA期肺腺癌患者进行临床病理研究
4. FDG uptake as a biological prognostic factor for recurrence in patients with surgically resected stage Ⅰ non-small cell lung cancer [C] . The First China-Japan-Korea conference of nuclear medicine . 2002

机译：手术切除的Ⅰ期非小细胞肺癌患者FDG摄取是复发的生物学预后因素
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Expression and prognostic value of GalNAc-T3 in patients with completely resected small (≤2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification [O] . Shilei Zhao, Tao Guo, Jinxiu Li, 2015

机译：IASLC / ATS / ERS分类后GalNAc-T3在完全切除的小（≤2cm）周围型肺腺癌患者中的表达及预后价值
7. P-166 * PROGNOSTIC VALUE OF THE IASLC/ATS/ERS CLASSIFICATION OF LUNG ADENOCARCINOMA IN RESECTED STAGE I DISEASE IN PURE CAUCASIAN PATIENTS [O] . O. Rena, P. Santos Pereira, R. Boldorini, 2014

机译：P-166 *纯白种人患者切除阶段I病中肺腺癌的预后价值/ ATS / ERS / ERS / ERS / ERS分类

MA 17.03 Prognostic Value of the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Completely Resected Stage IIIA(N2) NSCLC

著录项

相似文献

相关主题

期刊订阅